Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease Paris, May 28, 2026. The…
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code…
ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study First head-to-head, double-blind, randomized phase 4 study…
Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid Approval in…
Sanofi’s Board of Directors proposes the appointment of Christel Heydemann as an independent director Paris, March 5, 2026. The Board of Directors of Sanofi has…
Beyfortus study published in The Lancet Infectious Diseases shows benefit for infants beyond first RSV season First study showing that…
Sanofi’s Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease Recommendation supported by safety and efficacy…
Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma Approval based on…
ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors New AlphaMedix data…
Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation The fund…